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Background: The diagnosis of pulmonary aspergillosis is difficult because the sensitivity of the
conventional methods for the detection of Aspergillus such as culture and cytology, is poor. To
improve the sensitivity for Aspergillus detection, the detection of galactomannan antigen has
been investigated. The serum galactomannan (GM) antigen has been recognized to be a useful
tool for the diagnosis of invasive pulmonary aspergillosis. However, the utility of the galacto-
mannan antigen for the diagnosis of pulmonary aspergillosis other than invasive pulmonary
aspergillosis (IPA) has been unclear.
Methods: The GM antigen using serum and bronchial washing (BW) using bronchofiberscopy for
the diagnosis of pulmonary aspergillosis other than IPA were measured.
Results: In 45 enrolled patients, 7 patients had pulmonary aspergillosis, 5 of these patients had
chronic necrotizing pulmonary aspergillosis and 2 patients had allergic bronchopulmonary
aspergillosis. The area under the receiver operating characteristic (ROC) curve was 0.89 for
the BW GM antigen detection test, and 0.41 for the serum GM antigen detection test, suggest-
ing that the BW GM antigen detection test exhibits a better diagnostic performance than the
serum GM antigen detection test. The BW GM antigen detection test had a sensitivity of 85.7%
and a specificity of 76.3% at a cut-off level of 0.5, which was the optimal cut-off level ob-
tained by the ROC curve.3342 6111.
oo.co.jp (K. Tsushima).
3 Elsevier Ltd. All rights reserved.
13.04.007
GM antigen detection in the BW 1095Conclusion: The BW GM antigen detection test is thought to be a promising test for the diag-
nosis of pulmonary aspergillosis other than IPA.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Aspergillus species are ubiquitous fungi isolated from the
various environments such as the soil, foods, plant debris
and the indoor environment.1 Although there are
approximately Aspergillus 200 species, the pathogenic
species which cause pulmonary aspergillosis are limited.
Among these, the most common pathogenic species is
A. fumigatus, followed by A. flavus, A. niger and A.
terreus.1,2
Pulmonary aspergillosis involves a variety of clinical
entities. Invasive pulmonary aspergillosis (IPA) is a rapidly
progressive, fatal disease, and usually occurs in severely
immunocompromised patients.3 Allergic bronchopulmonary
aspergillosis (ABPA) is caused by an exaggerated immune
response to Aspergillus.4 Aspergilloma is a fungus ball that
develops in a pre-existing cavity in the lung parenchyma.5
Chronic necrotizing pulmonary aspergillosis (CNPA) is an
indolent, cavitary, infectious disease that occurs secondary
to local invasion by Aspergillus.6 Most patients with CNPA
have prior pulmonary disease, such as a healed tuberculosis
cavity.2
In every entity of pulmonary aspergillosis, the detec-
tion of Aspergillus from respiratory tract samples is very
important for reaching a precise diagnosis. However, the
roles of conventional diagnostic tools, such as cultures
obtained from respiratory tract samples, are limited by
their low sensitivity. According to the previous reports,
the culture sensitivity using respiratory tract samples
was reported to be 40% for IPA, and 17.9% for chronic
pulmonary aspergillsis (CPA).7,8 To improve the sensi-
tivity for Aspergillus detection, the detection of gal-
actomannan (GM) antigen has been investigated.9,10 GM
is a polysaccharide fungal cell wall component released
during hyphal growth in tissues and that can be detected
in body fluids. The serum GM antigen detection test has
been widely used as a useful tool for the diagnosis of
IPA.10 In addition, the detection of GM antigen in respi-
ratory tract samples, such as bronchoalveolar lavage
(BAL) and bronchial washing (BW), has also been inves-
tigated recently, and the GM antigen detection test using
the respiratory tract samples was reported to be a good
diagnostic tool using these samples.11e15 The detection
of GM antigen was reported to be more successful in the
BAL compared with in serum.11 However, the study
population in that report comprised primarily patients
with IPA. Thus, the utility of the GM antigen detection
test has been unclear for pulmonary aspergillosis other
than IPA.
Therefore, to evaluate the utility of the GM antigen
detection test for the diagnosis of pulmonary aspergillosis
other than IPA, we investigated the diagnostic perfor-
mance of the GM antigen detection test using the BW and
serum.Materials and methods
Patients
Patients at Tokyo Medical University Hospital who were
clinically suspected to have pulmonary aspergillosis be-
tween April 2008 and October 2011 were enrolled in this
study. Eligible patients displayed at least one of following
features: 1) a nodular shadow or cavity formation on chest
CT and an elevated C-reactive protein (CRP) level; 2)
asthma with bronchiectasis and mucoid impaction; 3) pul-
monary infiltrates on chest CT refractory to antibiotics.
Informed consent was obtained from each patient, and this
study was approved by the ethics committee of Tokyo
Medical University.
Detection of Aspergillus species
After finishing the routine procedures associated with
fiberoptic bronchoscopy, BW was obtained by the instilla-
tion of 50 mL of 0.9% sterile saline into the segment which
showed an abnormal shadow on the chest CT, and then
recovered as much of the saline as possible as BW. The lung
specimens obtained by transbronchial lung biopsy (TBLB)
were obtained from the same lesion as that which under-
went BW. The Platelia Aspergillus enzyme immunoassay
(EIA) (Bio-Rad Laboratories, Hercules, CA, USA) was per-
formed by SRL, Inc. (Tokyo, Japan) to measure the BW and
serum GM antigen levels. The serum sampling for the GM
was obtained on the same day as the performance of
bronchoscopy. The BW samples which were obtained for
the GM antigen detection test were used also for the fungal
and bacterial culture and cytology examinations. When a
diagnosis could not be made despite performing these ex-
aminations, then the Aspergillus precipitin test was per-
formed in the patients who agreed to be checked for the
presence of precipitant antibody. Next, Aspergillus pre-
cipitin tests were performed by SRL, Inc. using a double-gel
diffusion Ouchterlony assay (Mercia Diagnostics, Camber-
ley, UK).
Case definitions
The diagnostic criteria for CNPA and ABPA are shown in
Table 1. The diagnosis of proven CNPA was made by the
presence of at least one of the compatible symptoms such
as a persistent productive cough, at least one of the
compatible chest radiological images such as cavity for-
mation, and a positive serum Aspergillus precipitin test or
the positive isolation of Aspergillus species from respira-
tory tract samples by culture. Even if the existence of an
Aspergillus species could not be confirmed, the diagnosis of
possible CNPA was made when antibacterial therapy was
Table 1 The diagnostic criteria for CNPA and ABPA.
The diagnostic
criteria for CNPA
1. Symptoms (at least the one of following symptoms)
Persistent productive cough, hemoptysis, dyspnea, weight loss (>1 month)
2. Chest radiological images (at least the one of following chest radiological images)
Cavitary pulmonary lesions with evidence of paracavitary infiltrates, new cavitary formation
expansion of cavitary size over time, progressive pleural thickening, air-fluid level formation
3. Detection of Aspergillus species (at least the one of following methods)
Positive isolation of Aspergillus species from respiratory tract samples by culture
Positive serum Aspergillus precipitin test
4. Clinical course
Antibacterial therapy is not effective; however antifungal therapy is effective
Proven CNPA was defined by the presence of criteria 1e3.
Possible CNPA was defined by the presence of criteria 1, 2, and 4.
The diagnostic
criteria for ABPA
1. Asthma
2. Roentgenographic fleeting pulmonary opacities
3. Positive-skin test for Aspergillus
4. Eosinophilia
5. Precipitating antibodies (IgG) in serum
6. IgE in serum elevated (>1000 IU/mL)
7. Central bronchiectasis
8. Serum A. fumigatues-specific IgG and IgE
The presence of six of eight criteria confirmed the diagnosis.
CNPA, chronic necrotizing pulmonary aspergillosis; ABPA, allergic bronchopulmonary aspergillosis.
1096 Y. Kono et al.not effective, but the antifungal therapy was effective, for
the clinical symptoms and the chest radiological images
after the treatment. The diagnosis of ABPA was diagnosed
based on the Rosenberg-Patterson criteria, which were
described previously.16
Statistical analysis
The data are expressed as the means  SD. The diagnostic
performance was expressed as the sensitivity, specificity
and receiver operating characteristic (ROC) curve. The
optimal cut-off levels for the GM antigen detection tests
were determined by the ROC curves. Categorical variables
were compared by Fisher’s exact test or the Wilcoxon
signed-rank test, as appropriate. A p value 0.05 was
considered to be statistically significant.
Results
Characteristics of enrolled patients
During the study period, the GM antigens in the serum and
BW were assessed in 45 patients. Seven of the 45 enrolled
patients had pulmonary aspergillosis, four had proven CNPA
(4 male), one had possible CNPA (1 male) and two had ABPA
(2 female). The mean ages of the CNPA and ABPA patients
were 63.4  7.0 and 51.0 years, respectively. The diagnoses
of the other patients were 18 with lung cancer (5 males),
six with pulmonary tuberculosis (3 males), 10 with bacterialpneumonia (7 males) and four with nontuberculous myco-
bacteria (NTM) (2 males). The diagnosis of lung cancer was
based on the pathological findings of the TBLB. The diag-
nosis of pulmonary tuberculosis, bacterial pneumonia and
NTM was based on the BW culture.Characteristics of patients with pulmonary
aspergillosis
The characteristics of the patients with pulmonary asper-
gillosis are shown in Table 2. The underlying pulmonary
diseases of the patients with CNPA were four cases
complicated with chronic obstructive pulmonary disease
(COPD) and one of idiopathic pulmonary fibrosis (IPF). One
CNPA patient with COPD had prostate cancer, while another
CNPA patient with COPD had acquired immune deficiency
syndrome (AIDS). The abnormal shadows, such as cavitary
formation, had developed in the pre-existing cystic lesions
in three patients with COPD and in one patient with IPF. The
cavity had developed in the lung field, which appeared to
be normal on chest CT in one patient with COPD.
All patients with ABPA were complicated with bronchial
asthma, and showed bronchiectasis with mucoid impaction
and lung infiltrate on the chest CT findings. Blood exami-
nations revealed the presence of eosinophilia, an elevated
immunoglobulin E (IgE) level and A. fumigatues-specific IgE
in all ABPA patients.
TBLB was performed in two patients with CNPA and two
patients with ABPA. The existence of Aspergillus species
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GM antigen detection in the BW 1097was confirmed by TBLB in only one patient with ABPA. The
tissue specimen consisted of mucus containing many in-
flammatory cells and a few fungi identified as Aspergillus
species by immunohistochemistry. These results of the
other patients were nonspecific inflammation and fibrous
changes. The cytology of the BW did not indicate the
presence of hyphae in any of the cases. In the BW culture,
methicillin-susceptible Staphylococcus aureus (MSSA) was
isolated from one patient, and methicillin-resistant
Staphylococcus aureus (MRSA) and Candida albicans were
isolated from one patient. Aspergillus species were not
isolated from all patients on the BW cultures. Aspergillus
precipitin tests were performed in four patients. All of the
results of the Aspergillus precipitin tests were positive.
All of the patients with CNPA were treated with antibi-
otics before the antifungal therapies were started, and all
antibacterial therapies were performed as empiric therapy.
Two patents were treated with fluoroquinolones: levo-
floxacin (LVFX) and sitafloxacin (STFX). Three patients
were treated with b-lactam antibiotics: meropenem
(MEPM), cefepime (CFPM) and ampicillin/sulbactam (ABPC/
SBT). The mean duration of the antibacterial therapies was
seven days. No antibacterial therapies resulted in clinical
improvements. All of the patients with CNPA were treated
with intravenous voriconazole (VRCZ) initially. Because of a
drug-induced liver injury, intravenous VRCZ was changed to
intravenous micafungin (MCFG) followed by oral itracona-
zole (ITCZ) in one patient, and intravenous VRCZ was
changed to intravenous ITCZ followed by oral ITCZ in one
patient. The other three patients treated with intravenous
VRCZ followed by oral VRCZ. All of the patients showed a
clinical improvement following treatment with antifungal
therapies. The antifungal therapies were continued until
obvious improvement was confirmed. The mean duration of
antifungal therapies was six months. All of the patients
with ABPA were treated with an oral steroid, thus resulting
in an improvement of the symptoms related to bronchial
asthma.Results of the BW and serum GM antigen detection
tests
The mean volume of the recovered BW was approximately
20 mL. The mean BW GM antigen level was 1.97  1.75 in
the patents with pulmonary aspergillosis. The mean serum
GM antigen level was 0.30  0.32 in same patients with
pulmonary aspergillosis. The BW GM antigen level showed
a tendency to be higher than the serum GM antigen level
(p Z 0.08). The mean BW GM antigen level was
0.42  0.34, 0.30  0.28, 0.33  0.39, and 0.08  0.05 in
the patents with lung cancer, tuberculosis, bacterial
pneumonia and NTM, respectively. The mean serum GM
antigen level was 0.47  0.49, 0.25  0.20, 0.31  0.39,
and 0.23  0.01 in same patients with lung cancer,
tuberculosis, bacterial pneumonia and NTM, respectively.
In patients with diseases other than pulmonary aspergil-
losis, the mean BW GM antigen level was 0.34  0.33, and
the mean serum GM antigen level was 0.37  0.40. There
were no significant differences between the BW GM anti-
gen level and the serum GM antigen level in these patients
(p Z 0.66).
Figure 1 Receiver operating characteristic (ROC) curves for
the galactomannan (GM) antigen detection tests. A. ROC
curves for the bronchial washing (BW) GM antigen detection
test. The area under the ROC curve was 0.89. The optimal cut
off-level was calculated to be 0.5. At a cut-off level of 0.5,
the sensitivity and specificity for the diagnosis of pulmonary
aspergillosis were 85.7% and 76.3%, respectively. B. ROC curves
for the serum GM antigen detection test. The area under the
ROC curve was 0.41, thus suggesting that the serum GM antigen
detection test is not a useful diagnostic modality.
1098 Y. Kono et al.The sensitivity and specificity of the BW GM and serum
GM antigen detection tests at various interpretive cut-offs
are presented in Table 3. The BW GM antigen detection test
maintained a relatively high sensitivity and specificity at all
evaluated cut-off points, while the serum GM antigen
detection test failed to maintain an acceptable sensitivity
and specificity.
The ROC curves constructed for the BW and serum GM
antigen detection tests are presented in Fig. 1. The areas
under the ROC curves were 0.89 for the BW GM antigen
detection test, and 0.41 for the serum GM antigen detec-
tion test, thus suggesting that the BW antigen detection
test has a high accuracy, while the serum antigen detection
test is completely useless for diagnosing types of pulmonary
aspergillosis other than IPA. Based on the ROC curves, the
optimal cut off-level of the BW GM antigen detection test
was 0.5. When applying the cut-off level, the BW GM
antigen detection test had a sensitivity of 85.7% and a
specificity of 76.3%.
Discussion
This study investigated the utility of the BW GM antigen and
the serum GM antigen detection tests for detecting pul-
monary aspergillosis other than IPA. To evaluate the diag-
nostic performance, we constructed ROC curves for each
test. The area under the ROC curve was 0.89 for the BW GM
antigen detection test and 0.41 for the serum GM antigen
detection test, thus suggesting that the BW antigen
detection test is reliable, while the serum antigen detec-
tion test is completely useless. The BW GM antigen detec-
tion test had a sensitivity of 85.7% and a specificity of 76.3%
at a cut-off level of 0.5, which was the optimal cut off-
level obtained from the ROC curve. The sensitivity and
specificity are thought to be sufficient for use in clinical
practice.
The utility of the GM antigen detection test using res-
piratory tract samples was previously reported in a few
studies.11e15 However, most of the respiratory tract sam-
ples used in these studies were BAL. In our study, we used
the BW as the respiratory tract sample, because BW can be
obtained more easily and safely compared with BAL.
Although the utility of the BW antigen detection test has
been rarely investigated, the GM antigen detection was
reported to be more successful in the BW compared with inTable 3 The performance of the GM detection tests using
BW and serum.
Cut-off Sensitivity (%) Specificity (%)
BW GM
0.5 85.7 76.3
1.0 57.1 92.1
1.5 57.1 100.0
Serum GM
0.5 14.3 78.9
1.0 14.3 89.5
1.5 0.0 97.4
BW, bronchial washing; GM, galactomannan.the BAL.15 One possible explanation which was discussed in
that report was that the antigen-producing Aspergillus hy-
phae are primarily localized in bronchi. The other possible
explanation for why the GM in the BW was more detectable
than the GM in the BAL might be that GM in BW is not
diluted by lavage.17 Therefore, the level of GM in the BW
tends to be above the detection threshold. Although we did
not evaluate GM antigen in the BAL in this study, the high
sensitivity obtained in this study might be derived from this
feature of the BW.
GM was originally identified in Aspergillus species as a
potential serum diagnostic marker of IPA.9 Recently, the
serum GM antigen detection test is widely used as a method
to support the diagnosis of IPA. Marr et al. examined the
performance of the serum GM antigen detection test using
986 serum samples from 67 patients with IPA. In that
report, decreasing the cut-off level for positivity to 0.5
increased its sensitivity, with minimal loss of specificity.18
Therefore, the serum GM antigen detection test employ-
ing a cut-off level of 0.5 has been used for the diagnosis of
IPA in clinical practice in Japan. However, the utility of the
serum GM antigen detection test for the diagnosis of pul-
monary aspergillosis other than IPA is controversial. Kita-
sato et al. reported that the sensitivity of the serum GM
antigen detection test was 21.4% at a cut-off level of 1.5
GM antigen detection in the BW 1099and 50% at a cut-off level of 0.5 for CPA.8 However, the
specificity was not discussed in that report. Fujiuchi et al.
reported that at a cut-off level of 0.5, the sensitivity and
specificity for CNPA were 63.4% and 68.6% respectively.19 In
our study, the ROC analysis indicated that the serum anti-
gen detection test is completely useless for diagnosing
types of pulmonary aspergillosis other than IPA because the
area under the ROC curve was smaller than 0.5. At a cut-off
level of 0.5e1.5, a level employed in previous reports,
the sensitivity was 14.3e0%, which is thought to be too low
to use in clinical practice.
A comparison of the usefulness between the GM in the
serum and GM in the respiratory tract samples for the
diagnosis of pulmonary aspergillosis other than IPA has been
described in only a few previous reports. In a previous
report which evaluated the utility of the serum and BAL GM
antigen detection test in patients with aspergilloma, the
sensitivities of the serum and BAL GM antigen detection
tests were reported to be 38% and 92%, respectively, sug-
gesting that the BAL GM antigen detection test is more
useful than the serum GM antigen detection test for diag-
nosing aspergilloma.20 The vascular invasion or dissemina-
tion to other organs is uncommon in pulmonary aspergillosis
(except for IPA).21 Thus, only a small amount of the GM
antigen might enter the blood stream. Given our present
results, evaluating the GM antigen in the respiratory tract
samples might be better for the diagnosis of pulmonary
aspergillosis other than IPA than evaluating the serum level.
This study had several limitations. First, one patient with
possible CNPA was enrolled in this study. Because we defined
possible CNPA according to symptoms, chest radiological
images and the effectiveness of antifungal therapy, there is a
possibility that other types of fungal infection were diag-
nosed as possible CNPA. Second, the number of patients with
pulmonary aspergillosis was small. Third, the patients had
different underlying diseases. The fungal burden and the
development of pulmonary aspergillosis might depend on the
underlying diseases. Although many reports suggest that BAL
GM antigen detection tests add sensitivity to cytology and
culture in immunocompromised hosts, it has been reported
that the BAL GM antigen detection test does not add sensi-
tivity and only increases the likelihood of obtaining false-
positive results in non-immunocompromised hosts.22 There-
fore, the underlying diseases might influence the utility of
the GM antigen detection test. Fourth, three cases of CNPA
were treated with b-lactam antibiotics when the bronchos-
copy was performed. The drugs originating from fungi (such
as b-lactam antibiotics), but not all lots of b-lactam antibi-
otics, have been reported to possibly be associated with
false-positive test results.23,24 We did not evaluate any dif-
ferences in the reactivity to GM assay among the various lots
of b-lactam antibiotics used in this study. The use of b-lactam
antibiotics might have influenced the results of the GM an-
tigen detection test.
This is the first report which compared the usefulness of
the BW and serum GM antigen detection tests for the
diagnosis of pulmonary aspergillosis other than IPA. The BW
GM antigen detection test is thought to be a promising test,
because it has a relatively high sensitivity and specificity. In
contrast, the serum GM antigen detection test might not be
useful, according to the results of the ROC analysis. How-
ever, there were several limitations of this study that needto be considered when interpreting the results. Further
investigations are needed to confirm the role of the BW and
serum GM antigen detection tests for the diagnosis of pul-
monary aspergillosis other than IPA.
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